The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).
Age ≥18 years
Diagnosis of mantle cell lymphoma (MCL) established by histologic assessment
Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL
ECOG Performance Status (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death) less or equal to 2
Prior treatment for MCL with chemotherapy
Pregnant or breastfeeding women
Grade 2 or higher peripheral neuropathy
Known history of CNS (Central Nervous System) or leptomeningeal by MCL prior to study enrollment